APO RESEARCH · REPORT
Low Molecular Weight Heparin
Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage.
Product & engineering
Understand the product.
Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage.
Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da.
Selected research
Industry Research
Low Molecular Weight Heparin Industry Research Report 2026
Market perspective
Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage.
Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da.
Global Low Molecular Weight Heparin main players are Aspen, Sanofi-aventis, CSBIO, Dongying Tiandong Pharmaceutical, Techdow, etc. Top five companies hold a share above 55%. Europe is the largest market, with a share about 35%.
Read the full market overview
Report Scope
This report quantifies the global Low Molecular Weight Heparin market in revenue (US$ million) and, where applicable, sales volume (MT), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/MT) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Low Molecular Weight Heparin.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Low Molecular Weight Heparin Market by Company
Aspen
Sanofi-aventis
Pfizer
Opocrin
CSBIO
Dongying Tiandong Pharmaceutical
Changzhou Qianhong Bio-pharma
Techdow
Yantai Dongcheng Pharmaceutical Group
Low Molecular Weight Heparin Segment by Type
Enoxaparin
Dalteparin
Tinzaparin
Fraxiparine
Low Molecular Weight Heparin Segment by Application
Treatment of Venous Thromboembolism
Complications of Pregnancy
Cardioversion of Atrial Fibrillation/Flutter
Others
Low Molecular Weight Heparin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Low Molecular Weight Heparin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Low Molecular Weight Heparin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Low Molecular Weight Heparin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Low Molecular Weight Heparin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Low Molecular Weight Heparin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Low Molecular Weight Heparin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Enoxaparin
- Dalteparin
- Tinzaparin
- Fraxiparine
Applications
- Treatment of Venous Thromboembolism
- Complications of Pregnancy
- Cardioversion of Atrial Fibrillation/Flutter
- Others
Companies covered
- Aspen
- Sanofi-aventis
- Pfizer
- Opocrin
- CSBIO
- Dongying Tiandong Pharmaceutical
- Changzhou Qianhong Bio-pharma
- Techdow
- Yantai Dongcheng Pharmaceutical Group
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Low Molecular Weight Heparin by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 Enoxaparin
- 2.2.3 Dalteparin
- 2.2.4 Tinzaparin
- 2.2.5 Fraxiparine
- 2.3 Low Molecular Weight Heparin by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Treatment of Venous Thromboembolism
- 2.3.3 Complications of Pregnancy
- 2.3.4 Cardioversion of Atrial Fibrillation/Flutter
- 2.3.5 Others
- 2.4 Global Market Growth Prospects
- 2.4.1 Global Low Molecular Weight Heparin Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global Low Molecular Weight Heparin Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global Low Molecular Weight Heparin Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global Low Molecular Weight Heparin Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Low Molecular Weight Heparin Production by Manufacturers (2021-2026)
- 3.2 Global Low Molecular Weight Heparin Production Value by Manufacturers (2021-2026)
- 3.3 Global Low Molecular Weight Heparin Average Price by Manufacturers (2021-2026)
- 3.4 Global Low Molecular Weight Heparin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Low Molecular Weight Heparin Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global Low Molecular Weight Heparin Manufacturers, Product Type & Application
- 3.7 Global Low Molecular Weight Heparin Manufacturers Established Date
- 3.8 Global Low Molecular Weight Heparin Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Aspen
- 4.1.1 Aspen Low Molecular Weight Heparin Company Information
- 4.1.2 Aspen Low Molecular Weight Heparin Business Overview
- 4.1.3 Aspen Low Molecular Weight Heparin Production Capacity, Value and Gross Margin (2021-2026)
- 4.1.4 Aspen Product Portfolio
- 4.1.5 Aspen Recent Developments
- 4.2 Sanofi-aventis
- 4.2.1 Sanofi-aventis Low Molecular Weight Heparin Company Information
- 4.2.2 Sanofi-aventis Low Molecular Weight Heparin Business Overview
- 4.2.3 Sanofi-aventis Low Molecular Weight Heparin Production Capacity, Value and Gross Margin (2021-2026)
- 4.2.4 Sanofi-aventis Product Portfolio
- 4.2.5 Sanofi-aventis Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Low Molecular Weight Heparin Company Information
- 4.3.2 Pfizer Low Molecular Weight Heparin Business Overview
- 4.3.3 Pfizer Low Molecular Weight Heparin Production Capacity, Value and Gross Margin (2021-2026)
- 4.3.4 Pfizer Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Opocrin
- 4.4.1 Opocrin Low Molecular Weight Heparin Company Information
- 4.4.2 Opocrin Low Molecular Weight Heparin Business Overview
- 4.4.3 Opocrin Low Molecular Weight Heparin Production Capacity, Value and Gross Margin (2021-2026)
- 4.4.4 Opocrin Product Portfolio
- 4.4.5 Opocrin Recent Developments
- 4.5 CSBIO
- 4.5.1 CSBIO Low Molecular Weight Heparin Company Information
- 4.5.2 CSBIO Low Molecular Weight Heparin Business Overview
- 4.5.3 CSBIO Low Molecular Weight Heparin Production Capacity, Value and Gross Margin (2021-2026)
- 4.5.4 CSBIO Product Portfolio
- 4.5.5 CSBIO Recent Developments
- 4.6 Dongying Tiandong Pharmaceutical
- 4.6.1 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin Company Information
- 4.6.2 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin Business Overview
- 4.6.3 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin Production Capacity, Value and Gross Margin (2021-2026)
- 4.6.4 Dongying Tiandong Pharmaceutical Product Portfolio
- 4.6.5 Dongying Tiandong Pharmaceutical Recent Developments
- 4.7 Changzhou Qianhong Bio-pharma
- 4.7.1 Changzhou Qianhong Bio-pharma Low Molecular Weight Heparin Company Information
- 4.7.2 Changzhou Qianhong Bio-pharma Low Molecular Weight Heparin Business Overview
- 4.7.3 Changzhou Qianhong Bio-pharma Low Molecular Weight Heparin Production Capacity, Value and Gross Margin (2021-2026)
- 4.7.4 Changzhou Qianhong Bio-pharma Product Portfolio
- 4.7.5 Changzhou Qianhong Bio-pharma Recent Developments
- 4.8 Techdow
- 4.8.1 Techdow Low Molecular Weight Heparin Company Information
- 4.8.2 Techdow Low Molecular Weight Heparin Business Overview
- 4.8.3 Techdow Low Molecular Weight Heparin Production Capacity, Value and Gross Margin (2021-2026)
- 4.8.4 Techdow Product Portfolio
- 4.8.5 Techdow Recent Developments
- 4.9 Yantai Dongcheng Pharmaceutical Group
- 4.9.1 Yantai Dongcheng Pharmaceutical Group Low Molecular Weight Heparin Company Information
- 4.9.2 Yantai Dongcheng Pharmaceutical Group Low Molecular Weight Heparin Business Overview
- 4.9.3 Yantai Dongcheng Pharmaceutical Group Low Molecular Weight Heparin Production Capacity, Value and Gross Margin (2021-2026)
- 4.9.4 Yantai Dongcheng Pharmaceutical Group Product Portfolio
- 4.9.5 Yantai Dongcheng Pharmaceutical Group Recent Developments
5 Global Low Molecular Weight Heparin Production by Region
- 5.1 Global Low Molecular Weight Heparin Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global Low Molecular Weight Heparin Production by Region: 2021-2032
- 5.2.1 Global Low Molecular Weight Heparin Production by Region: 2021-2026
- 5.2.2 Global Low Molecular Weight Heparin Production Forecast by Region (2027-2032)
- 5.3 Global Low Molecular Weight Heparin Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global Low Molecular Weight Heparin Production Value by Region: 2021-2032
- 5.4.1 Global Low Molecular Weight Heparin Production Value by Region: 2021-2026
- 5.4.2 Global Low Molecular Weight Heparin Production Value Forecast by Region (2027-2032)
- 5.5 Global Low Molecular Weight Heparin Market Price Analysis by Region (2021-2026)
- 5.6 Global Low Molecular Weight Heparin Production and Value, YOY Growth
- 5.6.1 North America Low Molecular Weight Heparin Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe Low Molecular Weight Heparin Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China Low Molecular Weight Heparin Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan Low Molecular Weight Heparin Production Value Estimates and Forecasts (2021-2032)
6 Global Low Molecular Weight Heparin Consumption by Region
- 6.1 Global Low Molecular Weight Heparin Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global Low Molecular Weight Heparin Consumption by Region (2021-2032)
- 6.2.1 Global Low Molecular Weight Heparin Consumption by Region: 2021-2026
- 6.2.2 Global Low Molecular Weight Heparin Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Low Molecular Weight Heparin Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Low Molecular Weight Heparin Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Low Molecular Weight Heparin Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Low Molecular Weight Heparin Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Low Molecular Weight Heparin Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Low Molecular Weight Heparin Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa Low Molecular Weight Heparin Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa Low Molecular Weight Heparin Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global Low Molecular Weight Heparin Production by Type (2021-2032)
- 7.1.1 Global Low Molecular Weight Heparin Production by Type (2021-2032) & (MT)
- 7.1.2 Global Low Molecular Weight Heparin Production Market Share by Type (2021-2032)
- 7.2 Global Low Molecular Weight Heparin Production Value by Type (2021-2032)
- 7.2.1 Global Low Molecular Weight Heparin Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global Low Molecular Weight Heparin Production Value Market Share by Type (2021-2032)
- 7.3 Global Low Molecular Weight Heparin Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global Low Molecular Weight Heparin Production by Application (2021-2032)
- 8.1.1 Global Low Molecular Weight Heparin Production by Application (2021-2032) & (MT)
- 8.1.2 Global Low Molecular Weight Heparin Production Market Share by Application (2021-2032)
- 8.2 Global Low Molecular Weight Heparin Production Value by Application (2021-2032)
- 8.2.1 Global Low Molecular Weight Heparin Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global Low Molecular Weight Heparin Production Value Market Share by Application (2021-2032)
- 8.3 Global Low Molecular Weight Heparin Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 Low Molecular Weight Heparin Value Chain Analysis
- 9.1.1 Low Molecular Weight Heparin Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Low Molecular Weight Heparin Production Mode & Process
- 9.2 Low Molecular Weight Heparin Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Low Molecular Weight Heparin Distributors
- 9.2.3 Low Molecular Weight Heparin Customers
10 Global Low Molecular Weight Heparin Analyzing Market Dynamics
- 10.1 Low Molecular Weight Heparin Industry Trends
- 10.2 Low Molecular Weight Heparin Industry Drivers
- 10.3 Low Molecular Weight Heparin Industry Opportunities and Challenges
- 10.4 Low Molecular Weight Heparin Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst